Astria Therapeutics, Inc. - FORM 10-K - EX-23.1 - March 10, 2020

Attached files

file filename
EX-32.2 - EX-32.2 - Astria Therapeutics, Inc.a2240917zex-32_2.htm
EX-32.1 - EX-32.1 - Astria Therapeutics, Inc.a2240917zex-32_1.htm
EX-31.2 - EX-31.2 - Astria Therapeutics, Inc.a2240917zex-31_2.htm
EX-31.1 - EX-31.1 - Astria Therapeutics, Inc.a2240917zex-31_1.htm
EX-4.4 - EX-4.4 - Astria Therapeutics, Inc.a2240917zex-4_4.htm
10-K - 10-K - Astria Therapeutics, Inc.a2240917z10-k.htm

QuickLinks -- Click here to rapidly navigate through this document


Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

        We consent to the incorporation by reference in the following Registration Statements:

    1)
    Registration Statement (Form S-1 Nos. 333-225410 and 333-225734) of Catabasis Pharmaceuticals, Inc., and

    2)
    Registration Statement (Form S-3 No. 333-231441) of Catabasis Pharmaceuticals, Inc., and

    3)
    Registration Statement (Form S-8 Nos. 333-206394, 333-210229, 333-216793, 333-223721, 333-229643) pertaining to the equity incentive plans of Catabasis Pharmaceuticals, Inc.;

of our report dated March 10, 2020, with respect to the consolidated financial statements of Catabasis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Catabasis Pharmaceuticals, Inc. for the year ended December 31, 2019.

/s/ Ernst & Young LLP

Boston, Massachusetts
March 10, 2020



QuickLinks

Consent of Independent Registered Public Accounting Firm

Astria Therapeutics, Inc. Reports